Is CVS Stock Set for a Rebound?

Its market-shock drawdowns have been ordinary in depth, and some of its longest waits back to the old high came after falls the index barely noticed.

CVS Health (CVS) stock sits about 15% below its 52-week high after slipping 12.3% over the past month, and it is still up 34% over the trailing twelve months. Across the shocks it has already traded through, the depth is ordinary. The wait is not.

Its Deepest Shock Fall Was Smaller Than The Index's

Across the 15 market shocks it has traded through since 2007, CVS Health has fallen roughly in line with the S&P 500 on average, but individual episodes have varied widely. The deepest of those was a 39% fall during the 2008-2009 Global Financial Crisis, against 53% for the index. In that crash, holding the stock hurt less than holding the market . That 39% is not its outright record, though: over its full price history the worst fall was about 64%, in the early 2000s.

Its Third-Deepest Fall Came While The Market Barely Moved

Some of the costliest episodes sit elsewhere. During the 2023 SVB Regional Banking Crisis the index fell 6.7% while CVS Health fell 25%, its third-deepest drop on this record, then took about 28 months from its low to reclaim the prior high. In the 2016-2017 Trump Reflation Bond Selloff the index gave up 3.7% and the stock 18%, then needed about 54 months from that low. Both of those falls arrived while the market itself was calm, and against a median of about 10 months for the shocks it has fully recovered from, they are not dips but years of waiting; the slowest recovery on record ran about 69 months. Carrying a wait like that in one position is a different proposition from the Trefis High Quality Portfolio , which works from the point that spreading risk past roughly twenty names stops making a portfolio safer.

A Bigger Company, With Its Own Pressure Points Already Named

That history belongs to a business that has kept growing. Revenue over the trailing twelve months is about $415 billion, up 7.4% and in line with its own trend. In early August management raised full-year 2026 adjusted EPS guidance by $0.60, to a range of $7.90 to $8.10, and named its 2027 headwinds a quarter earlier than usual: membership declines at Caremark and continued pressure in the 340B program, set against an Aetna recovery that added more than $2 billion of year-over-year adjusted operating income in the first half of 2026. Management still called a 2027 adjusted EPS outlook of at least $8.44 reasonable. The 2027 pressures are not macro: they live in reimbursement, client renewals and drug pricing programs common to U.S. healthcare providers , and they bite in years the index spends going nowhere.